PL3117833T3 - Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza - Google Patents

Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza

Info

Publication number
PL3117833T3
PL3117833T3 PL16171392T PL16171392T PL3117833T3 PL 3117833 T3 PL3117833 T3 PL 3117833T3 PL 16171392 T PL16171392 T PL 16171392T PL 16171392 T PL16171392 T PL 16171392T PL 3117833 T3 PL3117833 T3 PL 3117833T3
Authority
PL
Poland
Prior art keywords
lif
inhibition
stem cells
tumor stem
tumorigenic potential
Prior art date
Application number
PL16171392T
Other languages
English (en)
Polish (pl)
Inventor
Angelo Luigi Vescovi
Brent Allan Reynolds
Original Assignee
Stemgen S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemgen S.P.A. filed Critical Stemgen S.P.A.
Publication of PL3117833T3 publication Critical patent/PL3117833T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL16171392T 2005-07-19 2006-07-19 Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza PL3117833T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70085905P 2005-07-19 2005-07-19
EP16171392.0A EP3117833B1 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif
PCT/IB2006/002296 WO2007010394A2 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
EP06795317.4A EP1904093B1 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by bmp-4

Publications (1)

Publication Number Publication Date
PL3117833T3 true PL3117833T3 (pl) 2019-06-28

Family

ID=37420973

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16171392T PL3117833T3 (pl) 2005-07-19 2006-07-19 Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza
PL06795317T PL1904093T3 (pl) 2005-07-19 2006-07-19 Hamowanie przez bmp-4 zdolności do tworzenia guzów przez komórki macierzyste guza

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06795317T PL1904093T3 (pl) 2005-07-19 2006-07-19 Hamowanie przez bmp-4 zdolności do tworzenia guzów przez komórki macierzyste guza

Country Status (13)

Country Link
US (2) US9220756B2 (enExample)
EP (2) EP3117833B1 (enExample)
JP (3) JP5189977B2 (enExample)
KR (2) KR101311061B1 (enExample)
AU (1) AU2006271308B2 (enExample)
CA (2) CA2615491C (enExample)
DK (2) DK3117833T3 (enExample)
ES (2) ES2686093T3 (enExample)
HR (1) HRP20181379T1 (enExample)
HU (2) HUE042197T2 (enExample)
NZ (2) NZ565172A (enExample)
PL (2) PL3117833T3 (enExample)
WO (1) WO2007010394A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
US8361955B2 (en) 2008-02-13 2013-01-29 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Offentlichen Rechts Methods for treating and preventing brain tumors based on bone morphogenetic proteins
CA2995310A1 (en) 2015-08-25 2017-03-02 Histide Ag Compounds for inducing tissue formation and uses thereof
EP3349778B1 (en) * 2015-09-17 2021-09-01 Histide AG Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
KR20180050744A (ko) * 2015-09-17 2018-05-23 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
KR20180052705A (ko) * 2015-09-17 2018-05-18 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
CA2998677A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2020138503A1 (ja) * 2018-12-28 2020-07-02 国立大学法人 東京大学 神経膠腫の治療および予防剤、脳腫瘍の悪性度のマーカーおよび脳腫瘍の予後マーカー、脳腫瘍の悪性度および予後の判定方法並びに腫瘍増殖を抑制する抗体
WO2026022122A1 (en) * 2024-07-23 2026-01-29 Eos Research Sa Checkpoint inhibitors in the treatment of glioblastoma multiforme

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
CA2104576C (en) * 1991-12-24 1997-04-15 George Kannourakis A method for the treatment of tumours and sarcomas
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
EP0756628B1 (en) * 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6036920A (en) 1996-05-09 2000-03-14 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization
JP4892131B2 (ja) * 1998-11-13 2012-03-07 ストライカー コーポレイション 癌の症状を緩和する方法
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
US20030162700A1 (en) * 2000-03-03 2003-08-28 Shipham Kylie Ann-Maree Method of treatment
WO2005026382A1 (en) 2003-09-12 2005-03-24 Stemcell Technologies Inc. Neural colony forming assay
JP2005098727A (ja) 2003-09-22 2005-04-14 Hosiden Corp 振動センサ
CA2546465A1 (en) 2003-12-05 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Identification, isolation and elimination of cancer stem cells
EP2789342A1 (en) * 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
WO2015050844A1 (en) * 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds

Also Published As

Publication number Publication date
EP1904093B1 (en) 2018-06-13
US9737589B2 (en) 2017-08-22
KR101311061B1 (ko) 2013-09-25
CA2615491A1 (en) 2007-01-25
HRP20181379T1 (hr) 2018-11-16
EP3117833B1 (en) 2019-01-23
CA2615491C (en) 2016-11-29
EP3117833A1 (en) 2017-01-18
KR20120125990A (ko) 2012-11-19
JP2012107063A (ja) 2012-06-07
ES2686093T3 (es) 2018-10-16
US20100167999A1 (en) 2010-07-01
KR101338533B1 (ko) 2013-12-12
JP2015057452A (ja) 2015-03-26
JP2009502771A (ja) 2009-01-29
NZ565172A (en) 2012-12-21
WO2007010394A3 (en) 2007-08-30
PL1904093T3 (pl) 2018-12-31
AU2006271308B2 (en) 2012-12-20
EP1904093A2 (en) 2008-04-02
KR20080082595A (ko) 2008-09-11
JP5189977B2 (ja) 2013-04-24
AU2006271308A1 (en) 2007-01-25
ES2710601T3 (es) 2019-04-26
WO2007010394A2 (en) 2007-01-25
HUE040063T2 (hu) 2019-02-28
CA2790675A1 (en) 2007-01-25
DK1904093T3 (en) 2018-09-03
DK3117833T3 (en) 2019-03-18
JP5891068B2 (ja) 2016-03-22
CA2790675C (en) 2016-12-20
US9220756B2 (en) 2015-12-29
NZ598031A (en) 2013-11-29
US20160228511A1 (en) 2016-08-11
HUE042197T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
ZA200900956B (en) Tumor suppression using placental stem cells
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
IL242282B (en) Enzyme Inhibiting Compounds
ZA201000022B (en) Novel amide derivative for inhibiting the growth of cancer cells
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
IL176942A0 (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
EP1888741A4 (en) TREATMENT OF ISCHEMIA WITH STEM CELLS
HUE042197T2 (hu) Tumor õssejtek tumorképzõ potenciáljának gátlása LIF segítségével
GB0605685D0 (en) Inhibition of tumour growth
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0803521D0 (en) A pharmaceutcal composition useful for the treatment of prostate cancer
GB0806872D0 (en) Compounds from myrothecium sp for inhibiting the growth of cancer cells
GB2426765B (en) The preparation of multipotent stem cells
EP1905445A4 (en) HUMBLER OF TUMOR GROWTH
GB0515305D0 (en) Stem cell markers 1
GB0508148D0 (en) An article of bedding
PL115454U1 (en) Shield of the radiator combined valve
EP1930425A4 (en) SEQUENCE CAPABLE OF IMPROVING THE EXPRESSION OF A GENE AT A MODERATELY LOW TEMPERATURE
ZA200606431B (en) The distribution of electricity
GB0526264D0 (en) Improvements to the tappping of small holes
GB0503289D0 (en) Principles of energy
GB0515309D0 (en) Stem cell markers 4
GB0515307D0 (en) Stem cell markers 2
GB0515310D0 (en) Stem cell markers 5